title: Nerve growth factor: an update on the science and therapy.
abstract: OBJECTIVE
  Nerve growth factor (NGF) is a key regulator of nociceptive pain and thus appears to be an interesting target molecule for an innovative class of analgesic medication. We set out to review the principles of neurogenic inflammation and results of anti-NGF regimens in animal studies as well as clinical trials with patients with back pain and osteoarthritis (OA).
  
  
  METHODS
  We searched using Google Scholar Search and Pubmed as well as through conference reports for articles and abstracts related to NGF and clinical trials using anti-NGF regimens. We report on efficacy findings and adverse events (AEs) related to these agents in this review.
  
  
  RESULTS
  We identified five full articles and eight abstract reports relating to anti-NGF agents studied for use in back pain and in OA.
  
  
  CONCLUSIONS
  Anti-NGF agents either alone or in combination with non-steroidal anti-inflammatory agents (NSAIDs) were more efficacious for the treatment of pain in a number of trials of knee and hip pain compared to NSAIDs alone. However, adverse effects that included rapidly progressive OA and joint replacement were more common in patients treated with anti-NGF and NSAIDs than either treatment alone. Anti-NGF treatment related neurologic symptoms including paresthesias, and potentially other types of adverse effects were usually transient but warrant additional investigation.
authors: Medizinische Klinik und Poliklinik III, University Hospital, Section of Rheumatology, Sigmund-Freud-Straße 25, D-53127 Bonn, Germany. Matthias.Seidel@ukb.uni-bonn.de
authors: M F
authors: MF
authors: Seidel
authors: B L
authors: BL
authors: Wise
authors: N E
authors: NE
authors: Lane
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D001416:Back Pain / Q000188:drug therapy*; D006801:Humans; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors*; D009443:Neuritis / Q000188:drug therapy*; D010003:Osteoarthritis / Q000188:drug therapy*
chemical_list: D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D061067:Antibodies, Monoclonal, Humanized; D020932:Nerve Growth Factor; C549319:tanezumab
keywords: Nerve growth factor; Neurogenic inflammation; Osteoarthitis; Receptor antagonists
references: Science. 1990 Mar 23;247(4949 Pt 1):1446-51
references: 2321006
references: Proc Natl Acad Sci U S A. 1990 Jul;87(14):5454-8
references: 2164684
references: Ann Rheum Dis. 2014 Sep;73(9):1665-72
references: 23852695
references: Osteoarthritis Cartilage. 2011 Jun;19(6):639-46
references: 21251985
references: Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2985-90
references: 17301229
references: N Engl J Med. 2010 Oct 14;363(16):1521-31
references: 20942668
references: Arthritis Rheumatol. 2016 Feb;68(2):382-91
references: 26554876
references: Semin Arthritis Rheum. 2010 Oct;40(2):109-26
references: 19481238
references: Brain Res. 1992 Jun 5;582(1):139-42
references: 1379871
references: J Knee Surg. 2011 Dec;24(4):251-64
references: 22303754
references: Pain. 2002 Sep;99(1-2):121-32
references: 12237190
references: Nature. 1989 Sep 14;341(6238):149-52
references: 2779653
references: Pain. 2010 May;149(2):386-392
references: 20350782
references: Nature. 1989 Jan 26;337(6205):362-4
references: 2911387
references: Eur J Pharmacol. 1984 Oct 30;106(1):199-201
references: 6529968
references: Biochem Soc Trans. 2006 Aug;34(Pt 4):587-90
references: 16856868
references: Annu Rev Neurosci. 2001;24:1217-81
references: 11520933
references: Ann Neurol. 1994 Aug;36(2):244-6
references: 8053664
references: Neuron. 1991 Nov;7(5):857-66
references: 1742028
references: J Bone Miner Res. 2007 Nov;22(11):1732-42
references: 17638576
references: J Pharmacol Exp Ther. 1999 Jun;289(3):1271-6
references: 10336516
references: Clin Orthop Relat Res. 1970 Sep-Oct;72:138-44
references: 5459776
references: Proc Natl Acad Sci U S A. 1983 Dec;80(23):7215-8
references: 6580641
references: Pain. 1999 Jun;81(3):245-255
references: 10431712
references: Curr Rheumatol Rep. 2012 Dec;14(6):583-8
references: 22948388
references: J Neurosci. 1993 May;13(5):2136-48
references: 8478693
references: Peptides. 1989 Mar-Apr;10(2):447-52
references: 2787910
references: J Physiol. 1986 Oct;379:407-16
references: 2435893
references: Eur J Neurosci. 1994 Dec 1;6(12):1903-12
references: 7704300
references: Science. 1984 Nov 2;226(4674):547-9
references: 6208609
references: Pain. 2011 Oct;152(10):2248-2258
references: 21696889
references: J Neurosci Res. 1995 Dec 15;42(6):775-83
references: 8847739
references: J Pain. 2012 Aug;13(8):790-8
references: 22784777
references: Vet Comp Orthop Traumatol. 2011;24(4):279-84
references: 21674121
references: Osteoarthritis Cartilage. 2011 Dec;19(12):1405-12
references: 22004765
references: Neuroscience. 1994 Sep;62(2):327-31
references: 7530342
references: Neurosci Lett. 1993 Apr 16;153(1):37-40
references: 8510822
references: Nat Med. 1995 Aug;1(8):774-80
references: 7585179
references: Curr Rheumatol Rep. 2001 Dec;3(6):484-8
references: 11709110
references: Neuron. 1991 May;6(5):845-58
references: 2025430